Last checked at 
LONDON (Alliance News) - Cambridge Cognition Holdings PLC on Monday said it is launching its first web-based product, CANTAB Recruit, an online patient recruitment portal for pharmaceutical and biotechnology firms to identify clinical trial participants.
CANTAB Recruit will be used to speed up the identification of trial participants in high-need areas such as Alzheimer's disease, and will pre-screen patients to help reduce failure rates.
This follows the recent demonstration of Cambridge Cognition's new wearable technology, Cognition Kit, intended for use in managing "day-to-day brain health".
The initial focus for CANTAB Recruit will be in Alzheimer's disease clinical trials, and the company said it is already in negotiations with pharmaceutical companies over the use of CANTAB Recruit to improve their recruitment programmes.
"The launch of these products is key to the company's long-term strategy to become the leading provider of scientifically proven technology to improve the understanding, diagnosis and treatment of mental health and wellbeing worldwide," said Chief Executive Officer Steven Powell in a statement.
Shares in Cambridge Cognition were untraded Monday morning. They last closed at 41.00 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.